News
TOKYO -- U.S. proxy advisory firm Institutional Shareholder Services (ISS) is recommending shareholders vote against the ...
3d
GlobalData on MSNEC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphomaThe European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...
Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...
Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...
Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...
This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502 ...
The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...
"I am extremely proud that Takeda has been recognized as one of the top ten employers in the world for 2024. This confirms ...
Defending champion Yuka Saso's bid for a third U.S. Open title in five seasons got off to a rocky start with a 2-over-par 74.
The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...
Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results